Introduction
============

Worldwide, lung cancer remains the most common cancer and the leading cause of cancer-related mortality. In 2018, there were an estimated 2.1 million new lung cancer cases (11.6% of the total cancer cases) and 1.8 million deaths (18.4% of the total cancer deaths) [@B1]-[@B3]. The incidence and mortality rates of lung cancer have significantly increased in recent years, and lung cancer has become a major public health problem in the developing world, including China [@B1], [@B4], [@B5].

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and about 66% of newly diagnosed NSCLC patients are already at stage III/IV [@B2]. Over the past decade, targeted therapy and immunotherapy have been dramatically changing the therapeutic scenario and providing better outcomes to advanced NSCLC patients identified based on their molecular profiles. Unfortunately, not all patients can benefit from these precision therapies, due to lack of an actionable biomarker (more than 40% of NSCLC patients) or to unavailability of genomic testing and/or precision therapies, especially for the many patients in the developing world. For those patients, platinum-based chemotherapy (PBC) is still the cornerstone of treatment and a commonly recommended choice [@B6]-[@B10]. Despite all efforts, the prognosis of stage IIIB/IV NSCLC remains extremely poor with a median survival of 7.9 months [@B11], and compared with precision therapies, the treatment with PBC alone is usually associated with worse survival, increased risk of toxic effects, and poor quality of life (QOL) [@B7], [@B9], [@B12]. Therefore, there is a pressing need to improve the efficacy and safety of PBC for those patients who are treated with PBC rather than precision therapies.

In China and some Asian countries, traditional Chinese medicines have been increasingly prescribed for advanced lung cancer patients in combination with PBC for synergistic interactions [@B13], [@B14]. Compound Kushen injection (CKI) is one of the commonly used anticancer Chinese patent medicines approved by the State Food and Drug Administration of China (Drug Approval Number: Z14021231) for the treatment of various cancers [@B15].

CKI is a mixture of natural compounds extracted from two medicinal herbs, Kushen (*Radix Sophorae* Flavescentis) and Baituling (*Rhizoma Smilacis* Glabrae). Active ingredients of CKI are matrine, oxymatrine, sophoridine, and N-methylcytisine [@B16], [@B17]. Many studies have shown that CKI and its active ingredients have notable anti-tumor activities [@B17], [@B18], [@B19], such as inhibiting cancer cell proliferation, invasion and metastasis [@B16], [@B20], [@B21], inducing tumor cell apoptosis [@B22], [@B23], reducing angiogenesis [@B21], inducing cell cycle arrest [@B20], [@B21], [@B23], inhibiting glycometabolism and amino acid metabolism [@B16], and reversing multidrug resistance [@B24], [@B25]. Besides, CKI can effectively increase immunologic function [@B26] and alleviate chemoradiotherapy-induced toxicity [@B21], [@B24], [@B25].

Emerging randomized controlled trials (RCTs) investigated the effects of CKI in combination with PBC on advanced NSCLC patients; however, the results were controversial. Some RCTs indicated that this combined therapy could improve the disease control rate (DCR), objective response rate (ORR), quality of life (QOL), and reduce adverse events [@B18], [@B19], but some trials found no significant changes in the above outcomes [@B27]-[@B32]. The effects of CKI combined with PBC for patients with stage III/IV NSCLC have never been systematically assessed. Therefore, it is necessary to assess the efficacy and safety of CKI combined with PBC for patients with stage III/IV NSCLC, aiming to provide optimal therapy for the specific subsets of patients.

Materials and Methods
=====================

We conducted this systematic review and meta-analysis following the PRISMA (Preferred Reported Items for Systematic Review and Meta-analysis) guidelines [@B33]. This study has been registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42019134892. Ethical approval was not required because the research materials were published studies.

Types of Studies
----------------

All RCTs comparing CKI plus PBC versus PBC alone were selected and assessed for inclusion in this study.

### Inclusion criteria

The participants included in this study should meet the following criteria: Diagnosis of stage III-IV NSCLC using the histopathological/cytological diagnostic criteria and TNM staging system [@B34]-[@B36] at least one bi-dimensionally measurable lesion; Karnofsky performance status (KPS) score [@B37] of at least 60; the range of Performance Status score from 0 to 2; life expectancy at least 3 months.

### Exclusion criteria

The trials were not RCTs; sample size of either group was less than 30 patients; diagnosis was not NSCLC; the staging was not at stage III/IV; the NSCLC diagnosis was not specified accurately; the trials in which baseline data of the participants were inconsistent; there were no relevant outcome measures; the chemotherapy regimen was not platinum-based chemotherapy (PBC) or not clarified; radiotherapy, surgery, chemotherapy, immunotherapy, or Chinese medicine therapy other than CKI had been administered within three months before randomization; full-text articles or data was not available.

Types of Interventions
----------------------

Experimental group: CKI plus PBC; control group: PBC only. In each RCT, the PBC regimen used in both experimental and control groups was the same. All PBC regimens were eligible.

Types of Outcome Measures
-------------------------

The primary clinical endpoint was the disease control rate (DCR). Objective response rate (ORR), quality of life (QOL), and toxic effects were defined as the secondary outcomes. According to the WHO criteria for reporting results of cancer treatment [@B38], [@B39], ORR and DCR were used to assess the short-term effectiveness. Improvement of QOL was considered when KPS score increased by 10 points or more after treatment. Anti-tumor drug toxicity was evaluated and classified as grades 0 to 4, according to Recommendations for Grading of Acute and Subacute Toxicity [@B38]. In this research, grades 3 and 4 toxicities were defined as severe toxicities.

Information Sources
-------------------

A comprehensive literature search was conducted by two independent researchers (HW Chen and HX Zhang). Published studies were retrieved in common databases including PubMed, Web of Science, ClinicalTrials.gov, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Wanfang Databases, the Chinese Scientific Journal Database, the Chinese Science Citation Database, and the Chinese Biomedical Literature Database. The last search date was April 20, 2019. In addition, we searched and evaluated the relevant systematic reviews and meta-analyses to select the potential studies from their references.

Search Strategy
---------------

The search details were conducted as follows (English database): {(\"Carcinoma, Non-Small-Cell Lung\" \[Mesh\] OR \"Carcinoma, Non-Small-Cell Lung\" \[Title/Abstract\] OR \"Carcinomas, Non-Small-Cell Lung\" \[Title/Abstract\] OR \"Lung Carcinoma, Non-Small-Cell\" \[Title/Abstract\] OR \"Lung Carcinomas, Non-Small-Cell\" \[Title/Abstract\] OR \"Non-Small-Cell Lung Carcinomas\" \[Title/Abstract\] OR \"Non-small Cell Lung Cancer\" \[Title/Abstract\] OR \"Non-Small-Cell Lung Carcinoma\" \[Title/Abstract\] OR \"Non-Small Cell Lung Carcinoma\" \[Title/Abstract\] OR \"Carcinoma, Non-Small Cell Lung\" \[Title/Abstract\] OR \"Non-Small Cell Lung Cancer\" \[Title/Abstract\]) AND (\"Compound Kushen injection\" \[Title/Abstract\] OR \"Fufang Kushen injection\" \[Title/Abstract\] OR \"Yanshu injection\")}.Chinese databases (CNKI, etc.) searches: {\"feixiaoxibaofeiai\" (\"carcinoma, non-small-cell lung\") AND (\"Fufangkushenzhusheye\" (\"Compound Kushen injection\" OR \"Fufang Kushen injection\" OR \"Yanshu injection\") AND Hualiao (\"chemotherapy\")}.

Study Selection
---------------

Two independent reviewers (HW Chen and T Li) screened all the candidate articles on the basis of title and abstract. The full texts were retrieved for further assessment according to the inclusion and exclusion criteria. All inclusion disagreements were resolved by consensus.

Data extraction
---------------

Three reviewers (HW Chen, XJ Yao, and HX Zhang) independently rated the included RCTs and extracted the data. If a trial reported ambiguous or incomplete data, reviewers contacted the corresponding author via email and/or phone for further information. The intention-to-treat (ITT) analysis was used to analyze the results whenever available. The characteristics of all included RCTs are summarized in Table [1](#T1){ref-type="table"}.

Risk of Bias in Individual Trials
---------------------------------

Two independent reviewers (HW Chen and T Li) appraised the risk of bias in the included trials using the Cochrane Risk of Bias Tool for Randomized Controlled Trials [@B38]. The following criteria were used to evaluate bias in each trial: random sequence generation; concealment of allocation; blinding of participants and personnel; blinding of outcome assessment; incomplete data; selective reporting; and other bias. The risk of bias was classified as \'unclear\', \'low\' or \'high\'.

Summary Measures and Data Synthesis
-----------------------------------

All analyses were performed using the Review Manager (RM) 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014), the Comprehensive Meta-Analysis (CMA) 3.0 (Biostat, Englewood, NJ, United States; 2016) and the Trial Sequential Analysis (TSA) software (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark; 2011). Dichotomous data were shown as the risk ratio (RR), risk difference (RD) or odds ratio (OR), and continuous data were shown as the weighted mean difference (WMD) or standardized mean difference (SMD) with a 95% confidence intervals (CI). Heterogeneity was assessed using the *I*^2^ statistic and Chi^2^ test. Substantial heterogeneity was considered when *I*^2^ \> 50% or *P* \< 0.01. If the hypothesis of homogeneity was not rejected, a fixed-effects model was used to estimate the summary RR (OR or RD), WMD (or SMD) and 95% CI; otherwise, a random-effects model was used [@B40]-[@B43].

Risk of Bias across trials
--------------------------

When the number of the included trials was ≥ 10, Egger\'s test and the funnel plots were used to examine the potential bias in the RCTs included in the meta-analysis [@B40], [@B44]-[@B46].

Additional analyses
-------------------

Sensitivity analysis, subgroup analysis and the Trial Sequential Analysis (TSA) were used to determine the robustness of results and calculate the required information size (RIS) in the meta-analysis [@B47]. A meta-regression analysis was also carried out to examine the potential heterogeneity and whether the moderator variables have an impact on the study effect size.

Results
=======

Study Selection
---------------

As shown in Figure [1](#F1){ref-type="fig"}, there were 2,035 records identified through the database search, 501 of them were duplicated and excluded. A total of 1,384 articles of case reports, reviews, letters, and basic researches were excluded after screening the title and the abstract. The full texts of 150 candidate papers were then screened and evaluated, and 113 were removed for the following reasons: unrelated with this research topic (n = 42); conference article (n = 1); not meeting inclusion criteria or meeting exclusion criteria (n = 70). Finally, 37 trials met the inclusion criteria. All the papers were in the Chinese language.

Study Characteristics
---------------------

Thirty-seven RCTs recruiting 3,272 patients were included (Table [1](#T1){ref-type="table"}) [@B18], [@B19], [@B27]-[@B32], [@B48]-[@B76]. All trials were conducted in China, and the articles were published from 2005 to 2017. All participants enrolled were patients with NSCLC at TMN stage III/IV. There were 1,670 and 1,602 patients in the experimental and control groups, respectively. The number of participants in each RCT varied from 60 to 144. The ages of the participants ranged from 18 to 80.

All RCTs included compared CKI combined with PBC versus PBC alone. Thirteen RCTs used TP (paclitaxel plus cisplatin), 10 RCTs used GP (gemcitabine plus cisplatin), 6 RCTs used NP (vinorelbine plus cisplatin), 2 RCTs used EP (Etoposide plus cisplatin), 1 RCT used DC (docetaxel plus carboplatin), 1 RCT used DP (docetaxel plus cisplatin), 1 RCT used TC (paclitaxel plus carboplatin), 1 RCT used PP (pemetrexed plus cisplatin) and 1 used RCT GC (Gemcitabine plus carboplatin), and 1 RCT used TP or GP regimens. In all experimental groups, CKI was synchronously administered with PBC for the patients. Twenty-five trials used 2 cycles of CKI for the patients in the experimental group, 8 trials used 3 cycles, and 4 trials used 4 cycles. The follow-up duration of the included RCTs varied from 1 to 30 months.

Methodological quality
----------------------

The risk of bias of all included RCTs was evaluated and summarized in Table [2](#T2){ref-type="table"}, Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. Randomization was used in all included studies, 28 studies clearly described appropriate randomization methods, risk of selection bias (random sequence generation) was low in these studies [@B18], [@B19], [@B27]-[@B29], [@B31], [@B50]-[@B52], [@B54]-[@B57], [@B59]-[@B62], [@B64]-[@B73], [@B75]. Another 9 RCTs did not describe how the randomization was accomplished and the risk of selection bias was unclear [@B30], [@B32], [@B48], [@B49], [@B53], [@B58], [@B63], [@B74], [@B76]. In all included RCTs, blinding of participants/personnel/outcome assessment was unclear. The data of all included trials were complete, the withdrawals and/or dropouts of patients were described and the reasons were reported. The risk of reporting bias was low. Any other bias was not clear.

Outcome measures
----------------

The findings of the meta-analyses are summarized in Table [3](#T3){ref-type="table"}.

### Disease control rate (DCR) and objective response rate (ORR)

All 37 included RCTs reported changes in DCR and ORR after the interventions. The pooled data showed that, compared with PBC alone, CKI plus PBC significantly improved DCR (RR = 1.11, 95% CI 1.07 to 1.15, *P* \< 0.00001; Figure [4](#F4){ref-type="fig"}) and ORR (RR = 1.30, 95% CI 1.20 to 1.40, *P* \< 0.00001; Figure [5](#F5){ref-type="fig"}). There was statistical homogeneity for both outcomes (both*I*² = 0%), and the fixed-effects model was used to combine the trials.

### Improvement of QOL

Twenty-three trials investigated the effects of different interventions on the QOL [@B18], [@B19], [@B28], [@B29], [@B31], [@B32], [@B20]-[@B52], [@B53], [@B58]-[@B60], [@B64]-[@B67], [@B69], [@B70], [@B72]-[@B74], [@B76]. Pooling data from these 23 studies showed that, compared with PBC alone, CKI plus PBC significantly improved QOL (RR = 1.73, 95% CI 1.55 to 1.92, *P* \< 0.00001; Figure [6](#F6){ref-type="fig"}). There was statistical homogeneity for this outcome (*I*² = 0%), and the fixed-effects model was used to combine the trials.

### Survival rates and other survival outcomes

Three trials reported the effect of CKI plus PBC on 1-year survival rate [@B62], [@B72], [@B76] and the result of meta-analysis showed that, compared with PBC alone, CKI plus PBC significantly increased 1-year survival rate (RR = 1.51, 95% CI 1.18 to 1.94, *P* = 0.001; Figure [7](#F7){ref-type="fig"}). There was statistical homogeneity for this outcome (*I*² = 0%), and the fixed-effects model was used to combine the trials.

Only one trial reported that there was no significant difference in the 2-year survival rate between groups (33.33% vs 23.81%, *P* \> 0.05) [@B72].

Several RCTs reported four other survival outcomes including overall survival (OS) [@B32], progression-free survival (PFS) [@B31], [@B32], median time to progression (mTTP) [@B29], [@B62], [@B63], median survival time (MST) [@B29], [@B31], [@B62], [@B72], but, because of the unextractable data and/or the diversity of survival outcomes in the included RCTs, meta-analysis was not possible for these outcomes.

### Toxicities

Twenty-four RCTs reported the effect of CKI on severe (grade 3 and 4) toxic effects according to the WHO criteria [@B38]. Compared with PBC alone, CKI plus PBC significantly reduced severe toxicities by 58% (RR = 0.42, 95% CI 0.37 to 0.49, *P* \< 0.00001; Figure [8](#F8){ref-type="fig"}).

The findings of the meta-analysis demonstrated that CKI plus PBC was associated with significant reductions in severe leukopenia (RR = 0.44, 95% CI 0.35 to 0.55, *P* \< 0.00001), anemia (RR = 0.22, 95% CI 0.12 to 0.38, *P* \< 0.00001), thrombocytopenia (OR = 0.51, 95% CI 0.32 to 0.82, *P* = 0.005), nausea and vomiting (RR = 0.41, 95% CI 0.30 to 0.56, *P* \< 0.00001), diarrhea (RR = 0.42, 95% CI 0.23 to 0.77, *P* = 0.004), stomatitis (RR = 0.31, 95% CI 0.13 to 0.74, *P* = 0.008), hair loss (RR = 0.47, 95% CI 0.24 to 0.89, *P* = 0.02). The differences between groups were statistically significant (Figure [8](#F8){ref-type="fig"}).

However, for severe liver injury (RR = 0.72, 95% CI 0.43 to 1.20, *P* = 0.21) and renal injury (RR = 0.41, 95% CI 0.11 to 1.58, *P* = 0.20), the differences between groups were not statistically significant (Figure [8](#F8){ref-type="fig"}).

There was no substantial heterogeneity for the above outcomes, and the fixed-effects model was used to combine the trials (Figure [8](#F8){ref-type="fig"}).

Publication Bias
----------------

The funnel plots of the DCR suggested possible publication bias in small trials (Figure [9](#F9){ref-type="fig"}A), the Egger\'s test (*P* = 0.745) of DCR demonstrated that there was no obvious publication bias. The funnel plots of ORR (Figure [9](#F9){ref-type="fig"}B), QOL (Figure [9](#F9){ref-type="fig"}C), and severe toxicities (Figure [9](#F9){ref-type="fig"}D) also showed possible publication bias due to small-study effects.

Subgroup and sensitivity analyses
---------------------------------

With regard to DCR, the primary outcome, the pooled data showed that CKI plus PBC increased DCR significantly (RR = 1.11, 95% CI 1.07 to 1.15, *P* \< 0.00001). Similar increases were observed when the subgroup and sensitivity analyses were performed based on the results of Cochrane Risk of Bias Tool (only including 28 RCTs with low risk of selection bias) (RR = 1.12, 95% CI 1.08 to 1.17, *P* \< 0.00001) [@B18], [@B19], [@B27]-[@B29], [@B31], [@B50]-[@B52], [@B54]-[@B57], [@B59]-[@B62], [@B64]-[@B73], [@B75], participants number ( ≥ 50 in each group) (RR = 1.11, 95% CI 1.06 to 1.16, *P* \< 0.0001), the cycle number of CKI \[2 cycles (RR = 1.11, 95% CI 1.06 to 1.15, *P* \< 0.00001), 3 cycles (RR = 1.12, 95% CI 1.04 to 1.20, *P* = 0.003), 4 cycles (RR = 1.10, 95% CI 0.97 to 1.24, *P* = 0.13)\], PBC regimens \[TP (RR = 1.13, 95% CI 1.06 to 1.21, *P* = 0.0002) , GP (RR = 1.11, 95% CI 1.05 to 1.18, *P* = 0.0004), NP (RR = 1.10, 95% CI 1.02 to 1.19, *P* = 0.003), EP (RR = 1.22, 95% CI 1.02 to 1.46, *P* = 0.03)\], or publication year (only including the studies published within 5 years) (RR = 1.14, 95% CI 1.07 to 1.22, *P* \< 0.0001) .

Trial sequential analysis (TSA) indicated the required information size for a reliable and conclusive meta-analysis had been reached, and that CKI combined with PBC was significantly superior to PBC alone (Figure [10](#F10){ref-type="fig"}), suggesting that the findings of the meta-analysis are robust for the DCR. The meta-regression analysis showed that the DCR was not improved with an increased cycle number (from 2 to 4) of CKI (Log OR = 0.543, *P* = 0.635; Figure [11](#F11){ref-type="fig"}).

For the ORR, QOL, and severe toxicity, the sensitivity and subgroup analyses showed similar results. Due to the limited number of included studies, the subgroup and sensitivity analyses were not available for the outcomes 1-year survival rate.

Discussion
==========

As an important anti-tumor drug in China, CKI is broadly used for treating many kinds of cancer. The efficacy and safety of CKI combined with chemotherapy for many cancers, such as esophageal cancer, breast cancer, hepatocellular carcinoma, colon cancer, etc. have been systematically evaluated [@B24], [@B25], [@B77]. A previous meta-analysis evaluated the effects of CKI combined with radiotherapy for NSCLC, indicating that CKI plus radiotherapy significantly improved the clinical efficacy and reduced adverse events [@B78], however, the efficacy and safety of CKI plus PBC for advanced NSCLC patients have never been evaluated. The present study is the first systematic review and meta-analysis evaluating the effects of CKI plus PBC for advanced lung cancer patients. Our results showed that CKI as an adjunctive treatment to PBC can bring some crucial clinical benefits to the NSCLC patients at stage III/IV. This combined therapy could improve the tumor responses and QOL with a low risk of chemotherapy-induced toxicities in patients with advanced NSCLC. Our findings are consistent with the results of those meta-analyses evaluating the effects of CKI on other cancers [@B24], [@B25], [@B77], [@B79].

This meta-analysis included a total of 3,272 patients. Trial sequential analysis on DCR showed that CKI combined with PBC was significantly superior to PBC alone, and the findings of the meta-analysis are robust for the primary endpoint. The meta-regression analysis showed that the DCR was not improved with an increased cycle number (from 2 to 4), indicating 2 cycles of CKI might be an optimal treatment choice.

Both DCR and ORR are considered as important parameters for evaluating the short-term efficacy of antitumor therapy [@B14], [@B80]-[@B82]. DCR, defined as the proportion of patients with complete response, partial response or no change, is regarded as the best response categorization to predict OS and progression-free survival (PFS). [@B80], [@B81] Therefore, it was defined as the primary clinical endpoint in our study. The pooled results of our meta-analyses clearly demonstrated that CKI plus PBC could significantly improve DCR (RR = 1.11, 95% CI 1.07 to 1.15) and ORR (RR = 1.30, 95% CI 1.20 to 1.40), suggesting that CKI increased the sensitivity of chemotherapy drugs and might also have synergic interactions with PBC. These are consistent with the results of previous meta-analyses evaluating the effects of CKI on the other cancers [@B24], [@B25], [@B77], [@B79], and the results of *in vitro* and *in vivo* experiments [@B24], [@B25]. Because the drug sensitivity is a major concern in chemotherapy for NSCLC [@B83], [@B84], the benefits observed with the CKI for these two short-term outcomes are of important clinical significance.

The follow-up duration of the included RCTs was relatively short (1-30 months) though some trials investigated the long-term efficacy of CKI and reported various survival outcomes. Because of the limited number of the included trials reporting the survival outcomes and/or unextractable data, meta-analysis was only available for 1-year survival rate, and the result of meta-analysis shows that, compared with PBC alone, CKI plus PBC significantly increased 1-year survival rate. This study could not comprehensively assess the long-term efficacy of CKI for advanced NSCLC. In the future, it is necessary to include and investigate more survival outcomes in the clinical trials to further assess the long-term efficacy of CKI [@B84], [@B85].

The adverse reactions caused by chemotherapy, such as gastrointestinal reactions and myelosuppression, are very common, which may lead to chemotherapy discontinuation, poor QOL, and the situation where harm outweighs the benefits of PBC in many patients treated by chemotherapy. The subgroup meta-analysis indicated that CKI plus PBC could significantly reduce adverse reactions, such as nausea and vomiting, leukopenia, thrombocytopenia, hemoglobin, stomatitis, diarrhea, hair loss, and anemia, etc. Our results demonstrated that CKI combined with PBC was associated with a significant improvement in QOL (*P* \< 0.00001), suggesting that combined treatment increases the tolerance to chemotherapy.

This meta-analysis has some limitations: all included studies were conducted in China and published in Chinese, some of the included studies were of the potential risk of bias, and the follow-up durations of all included trials were relatively short, etc. Therefore, more rigorous trials with longer follow-up periods are warranted to further assess the efficacy and safety of this combination therapy. Recently, a multicenter randomized controlled trial has been initiated to assess the efficacy of CKI in combination with chemotherapy in the treatment of elderly patients with advanced NSCLC [@B86]. Such high-quality trials will help strengthen the evidence-base for this therapy [@B87].

Conclusion
==========

From the available evidence, our meta-analysis indicates that Compound Kushen injection combined with platinum-based chemotherapy is more effective in improving clinical efficacy and alleviating the toxicity of chemotherapy than chemotherapy alone for the treatment of stage III/IV NSCLC. However, high-quality RCTs with survival outcomes are still needed to further confirm our findings.
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###### 

Principal characteristics of the studies included in the meta-analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference               Design   Sample size\   Outcomes measure                                       Treatment group   Control group (Chemotherapy regimen)   
                                   (T/C)                                                                                                                          
  ----------------------- -------- -------------- ------------------------------------------------------ ----------------- -------------------------------------- -------
  Ai XY, 2016 [@B48]      RCT      68/68          ORR, DCR, PFS, toxic effects                           CKI + DP          2                                      DP

  Chen H, 2012 [@B51]     RCT      34/34          ORR, DCR, QOL, toxic effects                           CKI + TP          3                                      TP

  Chen H, 2009 [@B49]     RCT      31/31          ORR, DCR                                               CKI + EP          2                                      EP

  Chen LG, 2011 [@B50]    RCT      40/40          ORR, DCR, QOL, toxic effects                           CKI + DC          2                                      DC

  Chen WF, 2015 [@B52]    RCT      53/52          ORR, DCR, QOL, toxic effects                           CKI + NP          2                                      NP

  Dong J, 2012 [@B27]     RCT      40/40          ORR, DCR                                               CKI + PP          4                                      PP

  Duan P, 2009 [@B53]     RCT      72/71          ORR, DCR, toxic effects                                CKI + GP          3                                      GP

  Hei X, 2016 [@B54]      RCT      34/34          ORR, DCR, QOL, toxic effects                           CKI + TP          3                                      TP

  Hu AL, 2014 [@B55]      RCT      46/46          ORR, DCR, toxic effects                                CKI + TP          3                                      TP

  Huang ZF, 2007 [@B56]   RCT      30/30          ORR, DCR                                               CKI + NP          2                                      NP

  Li CJ, 2011 [@B57]      RCT      40/40          ORR, DCR                                               CKI + TP          2                                      TP

  Liu GH, 2012 [@B60]     RCT      60/60          ORR, DCR, QOL, toxic effects                           CKI + GP          2                                      GP

  Liu YT, 2010 [@B59]     RCT      32/32          ORR, DCR, QOL, toxic effects                           CKI + TP          2                                      TP

  Liu Y, 2009 [@B58]      RCT      44/40          ORR, DCR, QOL                                          CKI + GP          2                                      GP

  Long SP, 2008 [@B61]    RCT      60/57          ORR, DCR, toxic effects                                CKI + TP          2                                      TP

  Lu WL, 2017 [@B18]      RCT      60/60          ORR, DCR, QOL                                          CKI + GP          4                                      GP

  Lu Y, 2005 [@B28]       RCT      32/30          ORR, DCR, QOL                                          CKI + EP          3                                      EP

  Pang DS, 2011 [@B29]    RCT      32/30          ORR, DCR, QOL, toxic effects                           CKI + TP          3                                      TP

  Sang XW, 2012 [@B62]    RCT      54/52          ORR, DCR, QOL, 1-year survival rate, toxic effects     CKI + NP          2                                      NP

  Song Y, 2014 [@B19]     RCT      30/30          ORR, DCR, QOL, toxic effects                           CKI + GP          2                                      GP

  Su WZ, 2007 [@B63]      RCT      50/30          ORR, DCR, toxic effects                                CKI + NP          2                                      NP

  Wang ZX, 2009 [@B64]    RCT      30/30          ORR, DCR, QOL, toxic effects                           CKI + GP          2                                      GP

  Wang H, 2009 [@B30]     RCT      76/68          ORR, DCR, toxic effects                                CKI + TC          2                                      TC

  Wang HJ, 2012 [@B68]    RCT      40/38          ORR, DCR                                               CKI + TP          2                                      TP

  Wang LY, 2009 [@B65]    RCT      45/45          ORR, DCR, QOL, toxic effects                           CKI + NP          4                                      NP

  Wang SF, 2016 [@B69]    RCT      51/46          ORR, DCR, QOL                                          CKI + TP          2                                      TP

  Wang YJ, 2015 [@B66]    RCT      30/30          ORR, DCR, QOL, toxic effects                           CKI + TP          4                                      TP

  Wang YB, 2015 [@B67]    RCT      56/52          ORR, DCR, QOL                                          CKI + TP          2                                      TP

  Wu YJ, 2011 [@B70]      RCT      34/42          ORR, DCR, QOL                                          CKI + TP/GP       2                                      TP/GP

  Wu HJ, 2006 [@B31]      RCT      43/44          ORR, DCR, QOL, toxic effects                           CKI + NP          3                                      NP

  Xiao P, 2012 [@B32]     RCT      53/50          ORR, DCR, QOL, toxic effects                           CKI + GP          2                                      GP

  Xu YQ, 2007 [@B73]      RCT      36/30          ORR, DCR, QOL                                          CKI + TP          2                                      TP

  Yu ZG, 2012 [@B74]      RCT      50/40          ORR, DCR, QOL, toxic effects                           CKI + GC          2                                      GC

  Zhang JW, 2015 [@B71]   RCT      60/60          ORR, DCR, QOL                                          CKI + GP          2                                      GP

  Zhang JJ, 2015 [@B72]   RCT      42/42          ORR, DCR, 1-year survival rate, 2-year survival rate   CKI + TP          3                                      TP

  Zhao K, 2012 [@B75]     RCT      43/43          ORR, DCR                                               CKI + GP          2                                      GP

  Zhou X, 2010 [@B76]     RCT      39/35          ORR, DCR, QOL, 1-year survival rate, toxic effects     CKI+ GP           2                                      GP
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**CKI:** Compound Kushen injection, **DC**: Docetaxel plus carboplatin, **DCR**: Disease control rate, **DP**: Docetaxel plus cisplatin, **EP**: Etoposide plus cisplatin, **GC**: Gemcitabine plus carboplatin, **GP**: Gemcitabine plus cisplatin, **NP**: Vinorelbine plus cisplatin, **ORR**: Objective Response Rate, **PBC**: Platinum-based chemotherapy, **PFS:** Progression-free survival, **PP**: Pemetrexed plus cisplatin, **QOL**: Quality of life, **RCT**: Randomized controlled trial, **TC**: Paclitaxel plus carboplatin, **T/C**: Treatment group/control group, **TP**: Paclitaxel plus cisplatin.

###### 

The methodologic quality of the included trials assessed using the Cochrane Risk of Bias Tool.

  Reference               Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other bias
  ----------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ------------
  Ai XY, 2016 [@B48]      ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Chen H, 2009 [@B49]     ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Chen LG, 2011 [@B50]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Chen H, 2012 [@B51]     \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Chen WF, 2015 [@B52]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Dong J, 2012 [@B27]     \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Duan P, 2009 [@B53]     ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Hei X, 2016 [@B54]      \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Hu AL, 2014 [@B55]      \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Huang ZF, 2007 [@B56]   \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Li CJ, 2011 [@B57]      \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Liu Y, 2009 [@B58]      ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Liu YT, 2010 [@B59]     \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Liu GH, 2012 [@B60]     \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Long SP, 2008 [@B61]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Lu Y, 2005 [@B28]       \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Lu WL, 2017 [@B18]      \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Pang DS, 2011 [@B29]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Sang XW, 2012 [@B62]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Song Y, 2014 [@B19]     \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Su WZ, 2007 [@B63]      ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Wang LY, 2009 [@B65]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Wang H, 2009 [@B30]     ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Wang ZX, 2009 [@B64]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Wang HJ, 2012 [@B68]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Wang SF, 2016 [@B69]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Wang YJ, 2015 [@B66]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Wang YB, 2015 [@B67]    \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Wu HJ, 2006 [@B31]      \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Wu YJ, 2011 [@B70]      \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Xiao P, 2012 [@B32]     ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Xu YQ, 2007 [@B73]      \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Yu ZG, 2012 [@B74]      ?                            ?                        ?                                        ?                                \+                        \+                    ?
  Zhang JJ, 2015 [@B72]   \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Zhang JW, 2015 [@B71]   \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Zhao K, 2012 [@B75]     \+                           \+                       ?                                        ?                                \+                        \+                    ?
  Zhou X, 2010 [@B76]     ?                            ?                        ?                                        ?                                \+                        \+                    ?

\+ = low risk of bias; ? = unclear risk of bias; - = high risk of bias.

###### 

Summary of the meta-analysis (pooled data across categories in the control group).

  Outcome or Subgroup                    Studies                  Participants   Statistical Method                Effect Estimate       *P*
  -------------------------------------- ------------------------ -------------- --------------------------------- --------------------- --------------
  DCR                                    37                       3272           Risk Ratio (M-H, Fixed, 95% CI)   1.11 \[1.07, 1.15\]   \< 0.00001\*
  Odds Ratio (M-H, Fixed, 95% CI)        1.73 \[1.45, 2.07\]      \< 0.00001\*                                                           
  Risk Difference (M-H, Fixed, 95% CI)   0.08 \[0.06, 0.11\]      \< 0.00001\*                                                           
  ORR                                    37                       3272           Risk Ratio (M-H, Fixed, 95% CI)   1.30 \[1.20, 1.40\]   \< 0.00001\*
  Odds Ratio (M-H, Fixed, 95% CI)        1.62 \[1.41, 1.87\]      \< 0.00001\*                                                           
  Risk Difference (M-H, Fixed, 95% CI)   0.11 \[0.08, 0.15\]      \< 0.00001\*                                                           
  QOL                                    23                       1924           Risk Ratio (M-H, Fixed, 95% CI)   1.73 \[1.55, 1.92\]   \< 0.00001\*
  Odds Ratio (M-H, Fixed, 95% CI)        2.78 \[2.29, 3.37\]      \< 0.00001\*                                                           
  Risk Difference (M-H, Fixed, 95% CI)   0.23 \[0.19, 0.27\]      \< 0.00001\*                                                           
  1-year survival rate                   3                        134            Risk Ratio (M-H, Fixed, 95% CI)   1.51 \[1.18, 1.94\]   0.001\*
  Odds Ratio (M-H, Fixed, 95% CI)        2.35 \[1.42, 3.88\]      0.0008\*                                                               
  Risk Difference (M-H, Fixed, 95% CI)   0.21 \[0.09, 0.32\]      0.0005\*                                                               
  Grade 3-4 toxicity                     24                       6842           Risk Ratio (M-H, Fixed, 95% CI)   0.42 \[0.37, 0.49\]   \< 0.00001\*
  Odds Ratio (M-H, Fixed, 95% CI)        0.35 \[0.30, 0.41\]      \< 0.00001\*                                                           
  Risk Difference (M-H, Fixed, 95% CI)   -0.09 \[-0.11, -0.08\]   \< 0.00001\*                                                           

**DCR**: Disease control rate, **ORR**: Objective Response Rate, **QOL**: Quality of life, **CI**: Confidence Interval.
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